Bby has stated in their recent updated report on acr dated the 25th of february 2011 that eli lilly is more likely that not to launch a takeover bid for acr in order to capture the full benefit of axiron sales.They have worked out a number of scenarios that value acr at $4.00(post dividend)if axiron captures 35% of the market to $7.00(post dividend) a share if they achieve a 50% market share.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.6¢ |
Change
-0.001(5.88%) |
Mkt cap ! $6.524M | |||
| Open | High | Low | Value | Volume |
| 1.7¢ | 1.7¢ | 1.5¢ | $19.90K | 1.210M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 463664 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.7¢ | 320000 | 2 |
View Market Depth
| Last trade - 15.56pm 25/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |